Sponsor
Medical University of Warsaw
Patient usefulness rating
91/100
Conditions
Brain Tumor Adult, Brain Tumor Benign, CerebroSpinal Fluid (CSF) Leak, Craniotomy +3
Eligibility
Inclusion Criteria: * Male or female at least 18 years old * Qualified for a craniotomy due to supratentorial intracranial tumor Exclusion Criteria: * Revision surgery due to recurrent brain tumor *…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
RTOG Foundation, Inc.
Patient usefulness rating
91/100
Conditions
Intracranial Meningioma
Eligibility
Inclusion Criteria: STEP 1 REGISTRATION * Aged \>= 18 years * Histologically confirmed diagnosis of WHO grade 1-3 meningioma * Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as…
AI-generated summary
This open-label, multicenter trial is testing whether the radiopharmaceutical drug [177Lu]Lu-DOTATATE helps adults whose brain meningioma (WHO grade 1–3) has progressed after prior treatment, compared with the standard of care. Participants are randomly assigned 2:1 to receive either [177Lu]Lu-DOTATATE or the standard therapy chosen by their doctor, and those on the standard arm may cross over to the radiopharmaceutical if their disease worsens. The study aims to learn whether [177Lu]Lu-DOTATATE can slow or stop tumor growth and how its safety compares with usual treatments. Key exclusions include NF2-related schwannomatosis, radiation-associated meningioma, prior SSTR2-targeted therapy, active infection, and significant cardiovascular disease.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
89/100
Conditions
Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm +3
Eligibility
Inclusion Criteria: * Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed * Recommended to receive…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
GT Medical Technologies, Inc.
Patient usefulness rating
89/100
Conditions
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic +2
Eligibility
Inclusion Criteria: 1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles. 2. Willing and able to provide informed consent and to participate in all evaluations. Exclusion Criteria:…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Neonc Technologies, Inc.
Patient usefulness rating
87/100
Conditions
Residual, Progressive or Recurrent Grade II or III Meningioma
Eligibility
Inclusion Criteria Patient must: 1. Have histologically confirmed WHO Grade II or III meningioma that is residual, progressive or recurrent following at least minimally safe resection and radiation therapy. Metastatic meningiomas are…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Patient usefulness rating
87/100
Conditions
Neurofibromatosis
Eligibility
* INCLUSION CRITERIA: To be eligible for entry into the study, candidates must meet all the following criteria: * Have the diagnosis of NF2 by established clinical criteria or genetic testing. *…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Dartmouth-Hitchcock Medical Center
Patient usefulness rating
87/100
Conditions
Brain Cancer, Brain Tumor, Brain Neoplasms, Primary Brain Tumor +8
Eligibility
CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion/exclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1.…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Baptist Health South Florida
Patient usefulness rating
85/100
Eligibility
Inclusion Criteria 1. Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed. 2. All patients must have developed recurrent disease or progressive…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
85/100
Conditions
Recurrent Meningioma
Eligibility
Inclusion Criteria: * Male or female patients of age \> 18 years * Patients with 68Ga-DOTATATE positive recurrent or progressive meningiomas, any World Health Organization (WHO) grade, who have progressed after first…
AI-generated summary
This study tests RYZ101, a radioactive therapy (225Ac-DOTATATE), for treating progressive or recurrent intracranial meningioma that has somatostatin receptors. It is for adults whose tumors are 68Ga-DOTATATE–positive recurrent or progressive meningiomas (WHO grades 1–3) after first-line treatment. The main goal is to see how well RYZ101 works by measuring progression-free survival at 6 months and to assess safety and the best dose. Secondary goals include tumor response on MRI, overall survival, and potential PET imaging biomarkers. The trial is currently recruiting and excludes people with serious heart disease, uncontrolled diabetes, liver cirrhosis, recent brain radiation, pregnancy, prior radiopharmaceutical therapy, or other major health issues.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Nationwide Children's Hospital
Patient usefulness rating
84/100
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma +9
Eligibility
All participants must meet the following inclusion and exclusion criteria. No exceptions will be given. Imaging studies to establish eligibility must be done within three weeks prior to enrollment. All other clinical…
AI-generated summary
- The study tests Lutathera (177Lu-DOTATATE) in people with recurrent or progressive high-grade CNS tumors or meningiomas that show uptake on DOTATATE PET scans.
- It has two age-based parts: Phase I for ages 4 to under 12 to find a safe dose, and Phase II for ages 12 to 39 to evaluate anti-tumor activity at the standard adult dose, given IV every 8 weeks for up to 4 cycles (about 8 months).
- Eligible participants must have had prior therapy and show DOTATATE PET uptake (Krenning score ≥2) and meet health and organ-function criteria; bulky disease or other exclusionary features may disqualify some patients.
- Key exclusions include bulky disease with mass effect, pregnancy or breastfeeding, certain other illnesses, and prior treatment with Lutathera or similar radiopharmaceuticals.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Tata Memorial Centre
Patient usefulness rating
84/100
Conditions
Primary Brain Tumors, Diffuse Glioma, Meningioma, Pituitary Adenoma +1
Eligibility
Inclusion Criteria: * Primary brain tumors * Age at irradiation: 18 to 70 years * Karnofsky Performance Status ≥ 60 * Diagnosis (histopathological/ radiological) of primary brain tumor with an expected survival…
AI-generated summary
This study compares proton radiotherapy with standard photon radiotherapy for adults with primary brain tumors that have a good prognosis and require focal cranial radiation. It is a randomized trial that will enroll 156 patients and assign them 1:1 to proton or photon therapy to see if proton therapy improves functional survival (time alive without recurrence, death, or radiotherapy-related complications). Eligible participants are adults aged 18–70 with a primary brain tumor (such as low‑grade glioma, ependymoma, meningioma, pituitary tumor, schwannoma, or craniopharyngioma) who have an estimated life expectancy over 5 years and a reasonable performance status, and who are planned for focal cranial radiotherapy. Exclusion criteria include prior re-irradiation, palliative radiotherapy, multifocal disease, planned whole-brain or craniospinal irradiation, and planned hypo-fractionated or stereotactic radiotherapy.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 83
Sponsor
University Hospital, Montpellier
Patient usefulness rating
83/100
Eligibility
Inclusion Criteria: * Over 18 years of age * Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024 * Tumour expressing SSTR2A on the…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 83
Sponsor
Centre Hospitalier St Anne
Patient usefulness rating
83/100
Conditions
Intracranial Meningioma, Meningioma, Health-related Quality of Life
Eligibility
Inclusion Criteria : * Inclusion Criteria: * Age ≥ 18 years * Diagnosis of intracranial meningioma on imaging and/or confirmed by surgery Exclusion Criteria: * Pregnant or breastfeeding * Individuals deprived of…
AI-generated summary
This non-interventional, single-assessment study tests the French version of the meningioma-specific quality-of-life questionnaire (MQOL-FR) to see if it validly and reliably measures patients’ well-being. It is for adults (≥18) with intracranial meningioma and uses online questionnaires (MQOL-FR, EQ-5D-5L, FACT-Br) that take about 30–45 minutes and can be completed in multiple sittings without changing usual care. The main goal is to evaluate MQOL-FR’s psychometric properties (dimensionality, internal consistency, construct/convergent validity) using 100 complete responses, with about 238 patients contacted to reach that target. Secondary aims describe QoL scores in the cohort and explore associations with tumor features and management; key exclusions include pregnancy/breastfeeding, inability to complete questionnaires independently, insufficient French, and legal deprivation of liberty or compulsory psychiatric care.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University Health Network, Toronto
Patient usefulness rating
83/100
Conditions
Cancer, Breast Cancer, Lung Cancer, Colon Cancer +14
Eligibility
Inclusion Criteria: 1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University Hospital Muenster
Patient usefulness rating
82/100
Conditions
Intraspinal Tumor, Juxtamedullary Tumor
Eligibility
Inclusion Criteria: * Adult, age ≥18 years, patients treated on intraspinal, extra medullary tumor * Patients must have sufficient cognitive and language skills to give informed consent Exclusion Criteria: * Absence of…
AI-generated summary
- This is a multicenter, recruiting study at University Hospital Muenster to track surgical outcomes and quality of life after removing juxta-medullary spinal tumors.
- It includes adults (18+) with intraspinal, extra-medullary tumors treated by surgery and collects data on the surgical approach, intraoperative monitoring, and recovery.
- The study aims to define benchmarks for how completely the tumor is removed, neurological function, and quality of life, and to learn which factors improve or worsen outcomes.
- Exclusion criteria include lack of informed consent or inability to consent, primary bone tumors invading the spinal space, and vertebral metastasis.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Ohio State University
Patient usefulness rating
82/100
Conditions
Pituitary Tumor, Meningioma, Rathke Cleft Cysts, Chordoma +4
Eligibility
Inclusion Criteria: * Patient is scheduled to undergo endoscopic endonasal surgery. Multiple, staged surgeries are not exclusionary * 18 years of age or older * The subject must in the investigator's opinion,…
AI-generated summary
The trial tests how quality of life changes over two years after endoscopic endonasal skull base surgery. It follows adults scheduled for this surgery at Ohio State University, with assessments before surgery and up to 24 months afterward. The study aims to measure quality of life using modern reconstruction techniques and to understand healing timelines and factors linked to worse outcomes. Participants must be 18 or older and able to consent and follow the study, and exclusions include prisoners, non-English speakers, and those not expected to survive to the 2-year follow-up.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Universitaire Ziekenhuizen KU Leuven
Patient usefulness rating
82/100
Conditions
Meningioma, Pituitary Disease, Pituitary Adenoma, Craniopharyngioma +2
Eligibility
Inclusion Criteria: * Adult patients scheduled for endoscopic endonasal skull base surgery Exclusion Criteria: * Pre-existing anosmia * Patients has a history of previous endoscopic endonasal skull base surgery
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Patient usefulness rating
82/100
Eligibility
Inclusion Criteria: * Adults (age ≥18 years) * Both sexes * Patients with rare brain tumors (incidence \<6 cases per 100,000 people/year) * Candidates for craniotomy for rare brain tumors * Native…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Seoul National University Hospital
Patient usefulness rating
81/100
Conditions
Brain Tumor, Primary, Meningioma, Schwannoma, Pituitary Adenoma +1
Eligibility
Inclusion Criteria for retrospective cohort * Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998 * Asymptomatic at first visit to the hospital * Patients who,…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Maastricht Radiation Oncology
Patient usefulness rating
80/100
Eligibility
Inclusion Criteria: * Meningioma WHO I, grading based on pathology or radiological features * Age ≥ 18 years. * Karnofsky Performance Score 70 or above. * Ability to comply with the protocol,…
AI-generated summary
- The trial tests whether advanced MRI can help identify meningioma patients who are at risk of cognitive decline after radiotherapy.
- It is for adults with WHO grade I meningioma who can undergo neuropsychological testing and MRI and who have a suitable performance status.
- The goal is to learn which brain areas are linked to cognitive decline so radiotherapy can be personalized to spare them and preserve thinking and memory.
- Key exclusions include prior cranial radiotherapy, pregnancy, being under 18, MRI contraindications, recent chemotherapy, and other conditions that could interfere with follow-up.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Patient usefulness rating
80/100
Conditions
Recurrent Meningioma
Eligibility
Inclusion Criteria: * Adult patient ≥ 18 years of age * Histologically confirmed diagnosis of meningioma (all grades, 1-3 per WHO CNS5, are eligible) * WHO performance status 0-2 * Measurable disease…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 79
Sponsor
Dana-Farber Cancer Institute
Patient usefulness rating
79/100
Eligibility
Inclusion Criteria: * Have histologically confirmed WHO grade I, II or III meningioma that is progressive or recurrent. Metastatic meningiomas are allowed. Participants with grade I tumors must have failed radiation therapy.…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Jona Hattangadi-Gluth
Patient usefulness rating
79/100
Conditions
Primary Brain Tumor, Glioma, Meningioma, Schwannoma
Eligibility
Inclusion Criteria: 1. Patients 18 years or older 2. Karnofsky performance status (KPS) ≥70 3. Life expectancy of ≥1 year 4. Primary brain tumor patients who will receive fractionated partial brain RT…
AI-generated summary
This study tests how fractionated brain radiotherapy affects brain tissue and cognitive function in people with primary brain tumors. It will enroll adults (18+) who will receive fractionated partial brain radiotherapy and have decent functional status (KPS ≥70) with at least one year expected survival. Participants will have MRI scans and neurocognitive tests before treatment and at 3, 6, and 12 months after treatment to track brain changes and cognitive outcomes. The goal is to identify brain regions and dose-related changes related to cognitive effects, to help design future cognitive-sparing radiotherapy. Exclusions include the inability to undergo contrast MRI and prior brain radiotherapy.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Universitaire Ziekenhuizen KU Leuven
Patient usefulness rating
79/100
Conditions
Cognition, Brain Tumor, Magnetic Resonance Imaging, Meningioma +2
Eligibility
Inclusion Criteria: * Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Centre Francois Baclesse
Patient usefulness rating
78/100
Conditions
Cavernous Sinus Meningioma, Proton-therapy, Photon Radiotherapy, Cognitive Impairment
Eligibility
Inclusion Criteria: * Cavernous sinus meningioma for which clinical target volume is larger than 3 centimeters * Anterior skull base meningioma, invading by contiguity the cavernous sinus can be included * Histologic…
AI-generated summary
This is an open-label, 1:1 randomized trial comparing proton therapy (PRT) with modern photon radiotherapy (XRT) for cavernous sinus meningioma. It is for adults aged 18 to 70 with histologically proven Grade I cavernous sinus meningioma where irradiation is planned and the target is larger than 3 cm. The study aims to learn whether proton therapy reduces long-term toxicity, especially cognitive and functional outcomes, compared with photon radiotherapy. Exclusions include higher-grade tumors (Grade II/III), prior brain irradiation, certain neurological diseases or MRI contraindications, pregnancy, and other conditions that could affect participation.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
St. Olavs Hospital
Patient usefulness rating
78/100
Eligibility
Inclusion Criteria: * Radiological diagnose of typical intracranial meningioma (homogenous contrast enhancement or dural attachment) * Indication for treatment due to growth, symptoms or both * Tumor location suggestive of vascular supply…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Weill Medical College of Cornell University
Patient usefulness rating
78/100
Eligibility
Inclusion Criteria: * High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent…
AI-generated summary
- This trial tests whether injecting Cu-64 DOTATATE and using a gamma probe during surgery can feasibly detect meningioma tumors in real time.
- It is for adults with meningioma who are planned for surgical resection based on MRI or pathology suggesting recurrence or residual disease.
- Researchers want to learn if intraoperative tumor counts match pre- and post-operative PET imaging and how these measurements relate to pathology and the completeness of tumor removal.
- Key exclusions include pregnancy or breastfeeding, certain skull-base surgeries where the probe can’t be used, allergy to somatostatin analogs, MRI contraindications, prior cranial radiation, or involvement in other meningioma trials.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 77
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
77/100
Conditions
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Eligibility
Inclusion Criteria: * Patients must have histologically confirmed World Health Organization (WHO) grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease * Patients must have…
AI-generated summary
This study tests whether nivolumab given with multi-fraction stereotactic radiosurgery, with or without ipilimumab, is safe and potentially effective for adults with recurrent WHO grade II-III meningioma that has returned after prior radiation. It is a phase I/II trial that starts with dose escalation to find a safe maximum dose, followed by a phase II portion where participants are randomized to two treatment cohorts. The main goals are safety and the maximum tolerated dose, and to assess tumor response on MRI. Secondary goals include duration of response, progression-free survival, overall survival, and exploratory immune and tumor genetic studies to identify biomarkers and resistance mechanisms. Key exclusions include recent chemotherapy or radiation to the target site, prior checkpoint inhibitor therapy, active autoimmune disease, pregnancy, and uncontrolled illness.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Klinikum Oldenburg gGmbH
Patient usefulness rating
77/100
Conditions
Craniopharyngioma, Obesity
Eligibility
Inclusion Criteria: 1. Diagnosed with craniopharyngioma for the first time 2. Age at diagnosis 18 years or less of age 3. Agreement from patient's parents or legal guardian as well as the…
AI-generated summary
- The KRANIOPHARYNGEOM Registry is a multicenter project that will collect and describe data on childhood brain tumors, starting with craniopharyngioma and also including related conditions like xanthogranuloma, Rathke’s pouch cysts, meningioma, pituitary adenoma, prolactinoma, and cystic brain malformations.
- It will prospectively gather information about how these conditions are diagnosed, treated, and followed over time.
- The registry is for patients diagnosed with craniopharyngioma for the first time, aged 18 years or younger, with consent from the patient and/or their parents or guardians.
- Exclusions are diagnosis after age 18 or a diagnosis other than craniopharyngioma.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Centre Hospitalier St Anne
Patient usefulness rating
76/100
Conditions
Quality of Life, Meningioma
Eligibility
Inclusion Criteria: * Patient aged 18 years or older * Diagnosis of intracranial meningioma confirmed by imaging or surgery Exclusion Criteria: * Pregnant or breastfeeding women (Article L1121-5) * Patients deprived of…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 75
Sponsor
Scott R. Plotkin, MD, PhD
Patient usefulness rating
75/100
Conditions
Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma +1
Eligibility
Eligibility Specific For MASTER PROTOCOL: Inclusion Criteria: \- Patients must have a pathogenic variant in the NF2 gene (either in the germline or in two NF2-related tumors) OR a confirmed diagnosis of…
AI-generated summary
The INTUITT-NF2 Master Study is a basket, multi-arm Phase II trial testing two targeted drugs, brigatinib and neratinib, in people with NF2-related schwannomatosis and progressive NF2 tumors (vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas). The study aims to learn whether these drugs are safe and can shrink or stabilize tumors by measuring radiographic response rates across tumor types. Eligible participants have an NF2 gene variant or meet NIH/Manchester criteria and show measurable progression of a target NF2-related tumor, and they must be at least 12 years old; key exclusions include recent chemotherapy or radiation to the target tumor, use of other investigational drugs, uncontrolled cardiovascular disease, and pregnancy—note that the brigatinib arm is currently closed to enrollment. About 80 people are planned to participate, with up to 40 per sub-study, and the study can follow participants for up to 10 years, allowing switching between sub-studies if tumors grow.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Centro di Riferimento Oncologico - Aviano
Patient usefulness rating
75/100
Eligibility
Inclusion Criteria: * Age ≥ 16 years; * Ability to express appropriate informed consent to treatment; * Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of…
AI-generated summary
This study tests whether using PET imaging that targets somatostatin receptors to guide higher-dose radiation therapy is safe and may improve control of high-risk meningiomas. It is for people aged 16 and older with high-risk meningiomas (grade III, or recurrent or residual grade II, or first diagnosis of grade II with residual) who have not had brain radiotherapy and who can provide informed consent. The trial aims to see if escalating radiation dose based on PET imaging is feasible and can increase progression-free survival. Key exclusions include refusing radiotherapy, having other cancer treatments, current pregnancy, certain early-stage tumors (Grade I or some Grade II after initial radical surgery), and inability to undergo MRI with MoC or PET.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 74
Sponsor
Nanjing Medical University
Patient usefulness rating
74/100
Conditions
Malignant Meningioma
Eligibility
Inclusion Criteria: 1. The patient voluntarily signs the informed consent and can complete the follow-up examination, evaluation and treatment; 2. Age 18-70 years old (both ends included), both male and female; 3.…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 73
Sponsor
Technische Universität Dresden
Patient usefulness rating
73/100
Eligibility
Inclusion Criteria: * histologically confirmed atypical (WHO grade II) or anaplastic (WHO grade III) meningioma with the indication for radiotherapy * MRI (within 24h post-operative, if not available than with a time…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 72
Sponsor
University of Zurich
Patient usefulness rating
72/100
Conditions
Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma +4
Eligibility
Inclusion Criteria: 1. Age 18 years or older on day of signing informed consent, female or male. 2. Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 70
Sponsor
Weill Medical College of Cornell University
Patient usefulness rating
70/100
Eligibility
Inclusion Criteria: * Adult patients with clinically suspected meningioma * Patients planned for surgery - undergoing preoperative workup * No contraindications to either radiotracer Exclusion Criteria: * Age less than 18 years…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 68
Sponsor
British Columbia Cancer Agency
Patient usefulness rating
68/100
Conditions
Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma +12
Eligibility
Inclusion Criteria: All subjects: * World health organization performance status 0-2 * Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years) * Patients must be able to…
AI-generated summary
DOTATOC PET/CT for Imaging NET Patients is being studied. Conditions: Neuroendocrine Tumors, Insulinoma, Gastrinoma +13 • Eligibility: Inclusion Criteria: All subjects: * World health organization performance status 0-2 * Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years) * Patients…. Goal: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; British Columbia Cancer Agency.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 68
Sponsor
British Columbia Cancer Agency
Patient usefulness rating
68/100
Eligibility
Inclusion Criteria: * Age ≥ 18 years old * Able and willing to comply with the study procedures * Intact meningioma requiring definitive radiation * Post-operative meningioma requiring adjuvant radiation * No…
AI-generated summary
This study tests whether using 68Ga-DOTATATE PET imaging can improve radiation therapy planning for meningioma. It is for adults with meningioma who need definitive radiation or post-operative adjuvant radiation. The trial, sponsored by the British Columbia Cancer Agency, compares RT contouring and planning with DOTATATE-PET guidance to planning without it to see if it improves tumor delineation and spares normal tissue. Exclusions include pregnancy or breastfeeding, claustrophobia or inability to lie still, and inability to provide informed consent.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 68
Patient usefulness rating
68/100
Conditions
Glioblastoma Multiforme, Meningioma
Eligibility
Inclusion Criteria * One prior resection of histologically-diagnosed World Health Organization (WHO) Grade III or IV glioma, or WHO grade II or III meningioma. * MRI evidence of disease recurrence * For…
AI-generated summary
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients is being studied. Conditions: Glioblastoma Multiforme, Meningioma • Eligibility: Inclusion Criteria * One prior resection of histologically-diagnosed World Health Organization (WHO) Grade III or IV glioma, or WHO grade II or III meningioma. * MRI evidence of…. Goal: In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nader Sanai.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 64
Sponsor
Memorial Sloan Kettering Cancer Center
Patient usefulness rating
64/100
Eligibility
Inclusion Criteria: Cohort A specific inclusion: * Histologically confirmed IDHwt, RB intact, grade II or III glioma that has recurred after first line therapy (consisting of at least maximum feasible surgical resection…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 64
Sponsor
NYU Langone Health
Patient usefulness rating
64/100
Eligibility
Inclusion Criteria: 1. Male or female subjects aged ≥ 18 years. 2. Karnofsky Performance Status ≥ 60. 3. Histologically confirmed diagnosis WHO grade I-III meningioma: a. For grade I meningioma, subjects must…
AI-generated summary
Phase II, single-arm, open-label trial testing Lutathera (177Lu-DOTATATE) given by IV every 8 weeks for four doses in adults with progressive or high‑risk meningioma that is Ga-DOTATATE PET-MRI positive. It targets adults 18 and older with WHO grade I–III meningioma whose disease is progressing or residual and requires positive DOTATATE uptake. The study aims to learn whether Lutathera is effective by measuring imaging changes before treatment and about 6 months after starting therapy. Key exclusions include NF2, radiation‑associated meningiomas, active infection or significant cardiovascular disease, HIV, active HBV or HCV, pregnancy, and recent other investigational cancer treatments. The trial is currently not recruiting.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ENROLLING_BY_INVITATIONRating 62
Sponsor
Central Hospital, Nancy, France
Patient usefulness rating
62/100
Eligibility
Inclusion Criteria: * Patients who underwent surgery for a meningioma at the University Hospital of Nancy between 2000 and 2022. Exclusion Criteria: * Patients who did not express their consent to participate…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
51/100
Eligibility
Inclusion Criteria: * Diagnosis 1. Dose Escalation Cohorts: Histologically confirmed diagnosis of brain cancer: 1. glioblastoma (GBM), 2. anaplastic astrocytoma (AA), 3. anaplastic oligodendroglioma (AO), 4. anaplastic mixed oligoastrocytoma (AMO), 5. low…
AI-generated summary
Safety Study of Afatinib for Brain Cancer is being studied. Conditions: Brain Cancer • Eligibility: Inclusion Criteria: * Diagnosis 1. Dose Escalation Cohorts: Histologically confirmed diagnosis of brain cancer: 1. glioblastoma (GBM), 2. anaplastic astrocytoma (AA), 3. anaplastic oligodendroglioma (AO), 4. anaplastic mixed…. Goal: The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer. Other purposes of this study are to: * find out what effects (good and bad) afatinib has; * see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies; * learn more about how afatinib might affect the growth of cancer cells; * look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug). Phase/Status/Sponsor: Unknown phase; COMPLETED; Santosh Kesari.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Wake Forest University Health Sciences
Patient usefulness rating
51/100
Conditions
Brain Tumors, Metastatic Disease
Eligibility
INCLUSION CRITERIA: * Adults \>18 years old. * Life expectancy of at least \> 30 weeks. * Must have received a prior course of at least 30 Gy fractionated whole or partial…
AI-generated summary
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors is being studied. Conditions: Brain Tumors, Metastatic Disease • Eligibility: INCLUSION CRITERIA: * Adults \>18 years old. * Life expectancy of at least \> 30 weeks. * Must have received a prior course of at least 30 Gy…. Goal: RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Wake Forest University Health Sciences
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Radiation Toxicity
Eligibility
DISEASE CHARACTERISTICS: * Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria: * No radiographic evidence of disease * Stable disease, defined as no tumor progression within…
AI-generated summary
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor is being studied. Conditions: Brain and Central Nervous System Tumors, Radiation Toxicity • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria: * No radiographic evidence of disease * Stable disease, defined as…. Goal: RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Case Comprehensive Cancer Center
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Eligibility
DISEASE CHARACTERISTICS: * Diagnosis of brain tumor or other brain disorder, including, but not limited to, 1 of the following: * Primary brain tumors * Brain metastases * Acoustic neuromas * Pituitary…
AI-generated summary
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders is being studied. Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of brain tumor or other brain disorder, including, but not limited to, 1 of the following: * Primary brain tumors * Brain metastases *…. Goal: RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably. PURPOSE: This clinical trial is studying the acute side effects in patients who are undergoing stereotactic radiosurgery for brain tumors or other brain disorders. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
City of Hope Medical Center
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Eligibility
Inclusion Criteria Patients must be at least 18 years of age. Patients must have either a primary or metastatic brain tumor(s). Patients must be in need of a surgical debulking or a…
AI-generated summary
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer • Eligibility: Inclusion Criteria Patients must be at least 18 years of age. Patients must have either a primary or metastatic brain tumor(s). Patients must be in need of a…. Goal: RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about how this treatment is used by the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; City of Hope Medical Center.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Wake Forest University Health Sciences
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed primary malignant brain tumor * Newly diagnosed, progressive, or recurrent disease * May have received prior radiotherapy with or without chemotherapy * Scheduled to begin single-agent temozolomide…
AI-generated summary
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed primary malignant brain tumor * Newly diagnosed, progressive, or recurrent disease * May have received prior radiotherapy with or without chemotherapy * Scheduled…. Goal: RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying changes in semen or sperm caused by temozolomide in patients with newly diagnosed, progressive, or recurrent primary malignant brain tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
INSYS Therapeutics Inc
Patient usefulness rating
51/100
Eligibility
Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg of oral morphine/day, at…
AI-generated summary
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Children's Oncology Group
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia +7
Eligibility
DISEASE CHARACTERISTICS: Case or control patient clinically eligible for a Pediatric Oncology Group (POG) frontline therapeutic protocol, whether or not the protocol was submitted to or approved by the physician's Institutional Review…
AI-generated summary
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +8 • Eligibility: DISEASE CHARACTERISTICS: Case or control patient clinically eligible for a Pediatric Oncology Group (POG) frontline therapeutic protocol, whether or not the protocol was submitted to or approved by…. Goal: RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not enroll in them, and develop strategies to increase enrollment on these clinical trials. Phase/Status/Sponsor: Unknown phase; COMPLETED; Children's Oncology Group.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma +2
Eligibility
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumors * Neuroblastoma * Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)(Ewing's sarcoma closed to accrual as of 5/19/03) * Osteosarcoma (closed to accrual as of…
AI-generated summary
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma is being studied. Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma +3 • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumors * Neuroblastoma * Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)(Ewing's sarcoma closed to accrual as of 5/19/03) * Osteosarcoma (closed…. Goal: Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Institutes of Health Clinical Center (CC)
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer +5
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor\*, including, but not limited to, the following: * Rhabdomyosarcoma * Other soft tissue sarcomas * Ewing's sarcoma family of tumors * Osteosarcoma * Neuroblastoma *…
AI-generated summary
ABT-751 in Treating Young Patients With Refractory Solid Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor\*, including, but not limited to, the following: * Rhabdomyosarcoma * Other soft tissue sarcomas * Ewing's sarcoma family of tumors *…. Goal: RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Institutes of Health Clinical Center (CC)
Patient usefulness rating
51/100
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer +5
Eligibility
DISEASE CHARACTERISTICS: * Histologically diagnosed solid tumor (i.e., breast and ovarian epithelial carcinomas) or lymphoma * Slides reviewed at the NCI Laboratory of Pathology * Failure on therapy of proven efficacy for…
AI-generated summary
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas is being studied. Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically diagnosed solid tumor (i.e., breast and ovarian epithelial carcinomas) or lymphoma * Slides reviewed at the NCI Laboratory of Pathology * Failure on therapy…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Institutes of Health Clinical Center (CC)
Patient usefulness rating
51/100
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both of the following criteria…
AI-generated summary
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Case Comprehensive Cancer Center
Patient usefulness rating
51/100
Eligibility
DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including, but not limited to,…
AI-generated summary
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including,…. Goal: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Virginia Commonwealth University
Patient usefulness rating
50/100
Conditions
Primary Brain Tumor, Glioblastoma, Astrocytoma, Oligodendroglioma +2
Eligibility
Inclusion Criteria: * Primary brain tumor diagnosis (grade I-IV) * \>/=2weeks post-cranial resection (if applicable) * \>/=1 month post-radiation therapy (if applicable) * Able to understand, speak, and read English * Absence…
AI-generated summary
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial is being studied. Conditions: Primary Brain Tumor, Glioblastoma, Astrocytoma +3 • Eligibility: Inclusion Criteria: * Primary brain tumor diagnosis (grade I-IV) * \>/=2weeks post-cranial resection (if applicable) * \>/=1 month post-radiation therapy (if applicable) * Able to understand, speak, and…. Goal: This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and acceptability of recruitment, enrollment, data collection procedures, and retention of individuals with PBT and insomnia in the behavioral health intervention, CBT-I, and investigate the potential benefits of CBT-I within this at-risk and understudied population. Phase/Status/Sponsor: Unknown phase; COMPLETED; Virginia Commonwealth University.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Abramson Cancer Center at Penn Medicine
Patient usefulness rating
49/100
Conditions
Meningioma, Hemangiopericytoma
Eligibility
Inclusion Criteria: * Histologically confirmed diagnosis of WHO I-III meningiomas and hemangiopericytomas: 1. WHO grade I : * Tumor that are newly diagnosed and tumors that are incompletely excised * Tumors that…
AI-generated summary
Proton Radiation For Meningiomas and Hemangiopericytomas is being studied. Conditions: Meningioma, Hemangiopericytoma • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of WHO I-III meningiomas and hemangiopericytomas: 1. WHO grade I : * Tumor that are newly diagnosed and tumors that are incompletely…. Goal: This is a Feasibility/Phase II study for patients with a diagnosis of WHO Grade I - III Meningioma \& Hemangiopericytoma brain cancer to be given standard dose Proton radiotherapy. The study will be performed in two phases: first, feasibility with an enrollment of 12 patients and then Phase Page 8 of 20 II, with an enrollment of an additional 38 patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Abramson Cancer Center at Penn Medicine.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
49/100
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma +21
Eligibility
Inclusion Criteria: * Histologically confirmed malignancy at either original diagnosis or relapse, including the following: * Solid tumor, including primary CNS tumors * Neurologic deficits in patients with CNS tumors must have…
AI-generated summary
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma is being studied. Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor +22 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy at either original diagnosis or relapse, including the following: * Solid tumor, including primary CNS tumors * Neurologic deficits in patients with…. Goal: This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
48/100
Conditions
Central Nervous System Tumor
Eligibility
Inclusion Criteria: * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe resection is indicated OR…
AI-generated summary
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System is being studied. Conditions: Central Nervous System Tumor • Eligibility: Inclusion Criteria: * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe…. Goal: The purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing (high grade) CNS tumors, primary non-gadolinium enhancing CNS tumors, and primary vestibular schwannoma. The primary objectives of the study is to see how well tozuleristide and the Canvas imaging system during surgical resection will show fluorescence among primary enhancing/high grade CNS tumors; and among the tumors that demonstrate tozuleristide fluorescence, to estimate the true positive rate and true negative rate of fluorescence in tissue biopsies, as well as sensitivity and specificity of tozuleristide fluorescence for distinguishing tumor from non-tumoral tissue. Phase/Status/Sponsor: Unknown phase; COMPLETED; John Yu.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Harry T Whelan, MD
Patient usefulness rating
47/100
Conditions
Brain Tumor, Recurrent
Eligibility
1. Age: ≥ 6 months and \< 18 years 2. Disease: Patients with relapsed or refractory brain tumors are eligible. Patients must have had histologic verification of malignancy at original diagnosis or…
AI-generated summary
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors is being studied. Conditions: Brain Tumor, Recurrent • Eligibility: 1. Age: ≥ 6 months and \< 18 years 2. Disease: Patients with relapsed or refractory brain tumors are eligible. Patients must have had histologic verification of malignancy…. Goal: The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults. There are currently few cases published involving the use of PDT in infratentorial (in the posterior fossa) brain tumors in general and specifically those occurring in children. Phase/Status/Sponsor: Unknown phase; COMPLETED; Harry T Whelan, MD.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of South Florida
Patient usefulness rating
46/100
Eligibility
INCLUSION CRITERIA: * ≥ 2 years and ≤ 21 years of age at the time of study entry * Scheduled to receive chemotherapy for: * Newly diagnosed: * Non-rhabdo soft tissue sarcomas,…
AI-generated summary
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer is being studied. Conditions: Cancer • Eligibility: INCLUSION CRITERIA: * ≥ 2 years and ≤ 21 years of age at the time of study entry * Scheduled to receive chemotherapy for: * Newly diagnosed: *…. Goal: RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of South Florida.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Pediatric Brain Tumor Consortium
Patient usefulness rating
46/100
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma +1
Eligibility
DISEASE CHARACTERISTICS: * Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of unknown primary site), defined by 1 of the…
AI-generated summary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia +2 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of unknown primary site), defined…. Goal: RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Pediatric Brain Tumor Consortium.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
44/100
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma +23
Eligibility
Inclusion Criteria: * Histologically confirmed and/or clinical and imaging evidence of a de novo mass that is likely to be a brain tumor * Amenable to debulking surgery or surgical resection or…
AI-generated summary
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors is being studied. Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma +24 • Eligibility: Inclusion Criteria: * Histologically confirmed and/or clinical and imaging evidence of a de novo mass that is likely to be a brain tumor * Amenable to debulking surgery…. Goal: This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.